For the third time in four months, Lupin Pharmaceuticals, one of India’s biggest suppliers of generic drugs to foreign markets, has been admonished by the Food and Drug Administration for a series of troubling quality-control issues at a manufacturing facility.

In a recent inspection report, the regulator cited the company for failing to thoroughly review unexplained deficiencies in batches of medicines and not taking “scientifically sound” steps to evaluate samples; delays in assessing health hazards; insufficiently investigating customer complaints, including an instance involving mold on medicines shipped to the U.S.; and a lack of oversight and training.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy